Takatoshi Kakuta
Overview
Explore the profile of Takatoshi Kakuta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
80
Citations
667
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hamano N, Komaba H, Tanaka H, Takahashi H, Takahashi Y, Hyodo T, et al.
Am J Nephrol
. 2025 Feb;
:1-9.
PMID: 39978330
Introduction: Recent experimental studies have reported that fibroblast growth factor 23 (FGF23) inhibits erythropoiesis by suppressing erythropoietin (EPO) production and downregulating the EPO receptor. Conversely, either endogenous or exogenous EPO...
2.
Soeda K, Komaba H, Nakagawa Y, Kawabata C, Wada T, Takahashi H, et al.
J Nephrol
. 2024 Mar;
37(5):1339-1349.
PMID: 38512372
Background: Hyponatremia is implicated in pathological bone resorption and has been identified as a risk factor for bone fracture in the general population. However, there are limited data on the...
3.
Ohashi Y, Toyoda M, Saito N, Koizumi M, Kanai G, Komaba H, et al.
Sci Rep
. 2023 Jan;
13(1):93.
PMID: 36639673
Two-thirds of urate is excreted via the renal pathway and the remaining one-third via the extra-renal pathway, the latter mainly via the intestine in healthy individuals. ABCG2, a urate exporter,...
4.
Nakagawa Y, Komaba H, Wada T, Takahashi H, Takahashi Y, Hyodo T, et al.
Am J Nephrol
. 2022 Dec;
53(11-12):767-774.
PMID: 36574760
Introduction: Sclerostin is an osteocyte-derived inhibitor of bone formation and is increased in kidney failure. Sclerostin might be involved in the pathogenesis of vascular calcification, but few studies have examined...
5.
Nakagawa Y, Komaba H, Hamano N, Tanaka H, Wada T, Ishida H, et al.
J Clin Endocrinol Metab
. 2021 Aug;
107(1):e95-e105.
PMID: 34423837
Context: Sclerostin is an osteocyte-derived inhibitor of bone formation and is increased in kidney failure, but its role in the pathogenesis of renal bone disease remains unknown. Objective: We aimed...
6.
Nakayama M, Hamada C, Yokoyama K, Tanno Y, Matsuo N, Nakata J, et al.
Sci Rep
. 2020 Oct;
10(1):17565.
PMID: 33067481
The ability to visualize intraluminal surface of peritoneal dialysis (PD) catheter and peritoneal cavity could allow elucidation of the cases of outflow problems, and provide information on changes to the...
7.
Nakagawa Y, Komaba H, Hamano N, Wada T, Hida M, Suga T, et al.
Kidney Int
. 2020 Jul;
98(4):970-978.
PMID: 32682522
The 2017 Kidney Disease: Improving Global Outcomes (KDIGO) guideline update suggests bone mineral density testing to assess fracture risk in patients with chronic kidney disease, but dual-energy X-ray absorptiometry is...
8.
Kakuta T, Sawada K, Kanai G, Tatsumi R, Miyakogawa T, Ishida M, et al.
Sci Rep
. 2020 Feb;
10(1):3290.
PMID: 32094398
Possible ectopic parathyroid hormone (PTH) production in adipose tissues surrounding hyperplastic parathyroid glands was examined in patients with secondary hyperparathyroidism (SHPT). In vitro culture of adipose tissues from 31 patients...
9.
Yasuda A, Seki T, Kametani Y, Koizumi M, Kitajima N, Oki M, et al.
Int J Endocrinol
. 2019 Mar;
2019:8708401.
PMID: 30915117
ACTH-independent Cushing's syndrome (CS) is mainly caused by cortisol-secreting adrenocortical tumours. It is well known that secondary adrenal insufficiency occurs after surgical resection of these tumours. In this regard, impaired...
10.
Kakuta T, Ishida M, Komaba H, Suzuki H, Fukagawa M
Ther Apher Dial
. 2018 Oct;
23(2):133-144.
PMID: 30311350
Our previous small-scale trial demonstrated an erythropoiesis stimulating agent (ESA)-sparing potential of the TORAYLIGHT NV (NV) dialyzer in hemodialysis patients with high interleukin-6 levels. We now retrospectively explored this ESA-sparing...